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Letters to the Editor
Ultrafiltration in Refractory Heart
Failure
We read with great interest the recent paper by Patarroyo et al. (1)
regarding the possible lack of association between hemodynamic
and renal function improvement in refractory heart failure patients
treated with slow continuous ultrafiltration (SCUF).
The authors pointed out that their findings refuted the hypoth-
esis that hemodynamic improvement with SCUF can translate into
direct renal improvement and cautioned the promise of potential
benefit of SCUF in the setting of severe refractory heart failure.
However, we believe that 2 additional reasons, rather than SCUF
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Circulation (@CircAHA) 0treatment per se, could explain their results.First, in this study, patients had possibly already developed acute
kidney injury before SCUF initiation, as suggested by the increase
in serum creatinine from 1.9  0.8 mg/dl to 2.2  0.9 mg/dl.
Thus, the further creatinine increase (2.4  1 mg/dl) after SCUF,
and the high need for transition to renal replacement therapy,
might only reflect the spontaneous ongoing acute renal injury
started before SCUF. Conversely, we cannot exclude that SCUF-
induced hemodynamic improvement have hampered the negative
clinical and prognostic trajectory of such an acute renal event.
Second, a SCUF-induced hypovolemia due to an excessive, or
excessively fast (when compared with patients’ plasma refilling rate
capacity), fluid removal, with consequent further renal injury,
seems to emerge from this study. Indeed, while hematocrit did not
change (from 31  4.3% to 31  4%; p  0.6), protein total
concentration significantly increased (from 5.9 1.2 g/dl to 6.6
0.6 g/dl; p  0.006) during SCUF. Changes in plasma volume
during SCUF may be monitored by evaluating changes in hemat-
ocrit fraction (in the absence of bleeding and blood transfusion)
that should parallel plasma protein changes (2,3). Thus, when
plasma volume remains stable, no net gain or loss of intravascular
proteins should be observed. In the present study, the divergent
behavior of hematocrit (unchanged) and proteins (increased)
suggests a decrease in blood volume, with a concomitant bleeding
that may have hindered hematocrit increase associated with blood
volume reduction.
Therefore, it is not surprising that a too aggressive and rapid
depletion of intravascular volume in patients with acute kidney
injury could be associated with lack of renal function recovery. A
more prudential, even if partial, dehydration by SCUF should be
targeted, or another kind of renal replacement modality chosen, in
these patients and, particularly, in those—like probably many in
this study—with an impending or overt cardiogenic shock (average
cardiac index was 1.8 [range: 1.48 to 2.25] l/min/m2). With these
clinical and hemodynamic conditions, no immediate recovery in
kidney function is likely after SCUF, despite the achievement of a
significant hemodynamic improvement.
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Reply
We thank Drs. Marenzi and Aspromonte for their thoughtful
comments, which seemed to share the same consideration we have
discussed at length that both cardiac and renal compromise may be
too far gone to benefit from hemodynamic improvements achieved
via slow continuous ultrafiltration (SCUF) in patients refractory to
standard medical therapy (1). Our nephrology consultants custom-
arily prescribe renal replacement therapy upfront if there were any
clinical suspicions of established or evolving acute kidney injury. In
addition, only those who had received at least 48 h of SCUF
without the need for renal replacement therapy conversion were
included in the analysis. Therefore, the likelihood of a progressive
acute kidney injury scenario is relatively low in our study cohort.
We agree with Drs. Marenzi and Aspromonte that excessive fluid
removal at a rate inadequately balancing plasma refill rate may pose
detrimental consequences. Nevertheless, our SCUF protocol was
collaboratively conducted by nephrologists and cardiologists with
direct central hemodynamic measurements as well as careful
clinical monitoring in a dedicated heart failure intensive care unit.
Therefore, we have reliable assurance that the large majority of
subjects were able to maintain adequate intravascular filling pres-
sures (Fig. 1 in the original paper). This may also be reflected by
the lack of significant changes in hemoglobin or albumin over time
(1). The divergence between total protein measurements and
hematocrit was likely due to the relatively large variabilities in a
relatively small sample size (of note, the mean admission totalprotein was 6.3  1.1 g/dl) rather than overzealous removal of salt
and volume.
The latest clinical guidelines in the care of patients with heart
failure stated that “ultrafiltration is reasonable for patients with
refractory congestion not responding to medical therapy” (2).
While there are theoretical benefits and successful attributes of
SCUF use in selective patients, recent prospective clinical trial data
have provided the same cautionary note that SCUF may not be
advantageous over intensive pharmacologic therapy in the setting
of worsening renal function (3). Indeed, the invasiveness and costs
associated with SCUF can only be justified if there is a consistent
and reproducible benefit over standard medical therapies in a
well-defined population. Therefore, it is our opinion that any
further alternative explanations of discrepancies between perceived
advantages and observed lack of benefits can only be clarified with
refinement in techniques for this challenging population and
further careful clinical investigations.
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